Prescribing patterns of antidepressants in Europe: Results from the Factors Influencing Depression Endpoints Research (FINDER) study

[1]  P. Cowen,et al.  Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines , 2008, Journal of psychopharmacology.

[2]  K. Demyttenaere,et al.  Factors influencing depression endpoints research (FINDER): Study design and population characteristics , 2008, European Psychiatry.

[3]  H. Volz,et al.  Patterns and prevalence of antidepressant drug use in the German state of Baden‐Wuerttemberg: a prescription‐based analysis , 2007, Pharmacoepidemiology and drug safety.

[4]  Hans-Jürgen Möller,et al.  World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care , 2007, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[5]  Maurizio Fava,et al.  Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. , 2006, The New England journal of medicine.

[6]  M. Kölch,et al.  Antidepressant use in children and adolescents in Germany. , 2006, Journal of child and adolescent psychopharmacology.

[7]  M. Fava,et al.  An Open-label Study of Duloxetine for the Treatment of Major Depressive Disorder: Comparison of Switching Versus Initiating Treatment Approaches , 2005, Journal of clinical psychopharmacology.

[8]  J. Rojo,et al.  Antidepressant combinations: epidemiological considerations , 2005, Acta psychiatrica Scandinavica. Supplementum.

[9]  J. Rojo,et al.  Use of antidepressant combinations: which, when and why? Results of a Spanish survey , 2005, Acta psychiatrica Scandinavica. Supplementum.

[10]  K. Lohr,et al.  Efficacy and Safety of Second-Generation Antidepressants in the Treatment of Major Depressive Disorder , 2005, Annals of Internal Medicine.

[11]  F. López-Muñoz,et al.  Management of depression in primary care: a survey of general practitioners in Spain. , 2005, General hospital psychiatry.

[12]  I. Reid,et al.  Efficacy and Tolerability of Tricyclic Antidepressants and SSRIs Compared With Placebo for Treatment of Depression in Primary Care: A Meta-Analysis , 2005, The Annals of Family Medicine.

[13]  Eugene S. Paykel,et al.  Size and burden of depressive disorders in Europe , 2005, European Neuropsychopharmacology.

[14]  B. D'avanzo,et al.  Antidepressant drug consumption and public health indicators in Italy, 1955 to 2000. , 2005, The Journal of clinical psychiatry.

[15]  M. Posternak,et al.  Which factors influence psychiatrists' selection of antidepressants? , 2004, The American journal of psychiatry.

[16]  R. Kessler,et al.  Psychotropic drug utilization in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project , 2004, Acta psychiatrica Scandinavica. Supplementum.

[17]  I. Reid,et al.  Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis , 2003, BMJ : British Medical Journal.

[18]  B. Sleath,et al.  Sociological influences on antidepressant prescribing. , 2003, Social science & medicine.

[19]  T. Furukawa,et al.  Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review , 2002, BMJ : British Medical Journal.

[20]  J. Olie,et al.  Résultats d'une enquête sur l'usage des antidépresseurs en population générale française , 2002 .

[21]  H. Möller,et al.  World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance Treatment of Major Depressive Disorder and Treatment of Chronic Depressive Disorders and Subthreshold Depressions , 2002, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[22]  M. Posternak,et al.  Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? , 2002, The American journal of psychiatry.

[23]  H. Möller,et al.  World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and Continuation Treatment of Major Depressive Disorder , 2002, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[24]  R. Stafford,et al.  National Patterns of Medication Treatment for Depression, 1987 to 2001. , 2001, Primary care companion to the Journal of clinical psychiatry.

[25]  H. van Marwijk,et al.  Antidepressant prescription for depression in general practice in the Netherlands , 2001, Pharmacy World and Science.

[26]  I. Hindmarch,et al.  Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors , 2000, Acta psychiatrica Scandinavica. Supplementum.

[27]  R D Farmer,et al.  The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared. , 2000, Journal of affective disorders.

[28]  A. Claxton,et al.  Selective serotonin reuptake inhibitor treatment in the UK: Risk of relapse or recurrence of depression , 2000, British Journal of Psychiatry.

[29]  John Cornell,et al.  A Systematic Review of Newer Pharmacotherapies for Depression in Adults: Evidence Report Summary: Clinical Guideline, Part 2 , 2000, Annals of Internal Medicine.

[30]  I. Anderson,et al.  Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. , 2000, Journal of affective disorders.

[31]  J. Deakin,et al.  Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines , 2000 .

[32]  J. Lépine,et al.  DEPRES II (Depression Research in European Society II): a patient survey of the symptoms, disability and current management of depression in the community. DEPRES Steering Committee. , 1999, International clinical psychopharmacology.

[33]  D. Sclar,et al.  What Factors Influence the Prescribing of Antidepressant Pharmacotherapy? An Assessment of National Office-Based Encounters , 1998, International journal of psychiatry in medicine.

[34]  A. Montejo,et al.  [Pattern of usage of new antidepressants in clinical practice]. , 1998, Actas luso-espanolas de neurologia, psiquiatria y ciencias afines.

[35]  R. Brooks.  EuroQol: the current state of play. , 1996, Health policy.

[36]  M. Zetin,et al.  Rational antidepressant selection: applying evidence-based medicine to complex real-world patients. , 2006, Psychopharmacology bulletin.

[37]  Nice.  Depression: management of depression in primary and secondary care , 2005 .

[38]  J. Lépine,et al.  [Antidepressants consumption in the global population in France]. , 2002, L'Encephale.

[39]  J. Markowitz,et al.  Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. , 2000, The American journal of psychiatry.

[40]  J. Markowitz,et al.  Background information and treatment recommendations for patients with HIV/AIDS , 2000 .

[41]  G. Huston.  The Hospital Anxiety and Depression Scale. , 1987, The Journal of rheumatology.